MUSTANG BIO, INC.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
MBIO$0.45+15.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| · · · · | ||||||
| ASSETS · · | ||||||
| Current Assets: · · | ||||||
| Cash and cash equivalents | | $6,839 | | $6,234 | ||
| Other receivables | | | 402 | | | 3,879 |
| Prepaid expenses and other current assets | | 200 | | 1,233 | ||
| Property, plant and equipment, held for sale | | 1,165 | | — | ||
| Total current assets | | 8,606 | | 11,346 | ||
| | | | ||||
| Property, plant and equipment, net | | 371 | | 3,247 | ||
| Restricted cash | | - | | 750 | ||
| Other assets | | 250 | | 833 | ||
| Operating lease right-of-use asset, net | | | 81 | | | 1,566 |
| Total Assets | | $9,308 | | $17,742 | ||
| | | | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| Current Liabilities: | | | ||||
| Accounts payable and accrued expenses | | $9,486 | | $14,017 | ||
| Payables and accrued expenses - related party | | | 2,667 | | | 834 |
| Operating lease liabilities - short-term | | | 456 | | | 520 |
| Total current liabilities | | 12,609 | | 15,371 | ||
| | | | ||||
| Deferred income | | 150 | | 270 | ||
| Operating lease liabilities - long-term | | | 422 | | | 1,978 |
| Total Liabilities | | 13,181 | | 17,619 | ||
| | | | | |||
| Commitments and Contingencies (Note 8) | | | ||||
| | | | ||||
| Stockholders’ Equity | | | ||||
| Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | | — | | — | ||
| Common stock ($0.0001 par value), 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively | | | ||||
| Class A common shares, 845,385 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | | — | | — | ||
| Common shares, 985,972, and 166,974 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | | 5 | | 1 | ||
| Common stock issuable, 69,046 and 7,061 shares as of December 31, 2024 and December 31, 2023, respectively | | 611 | | 591 | ||
| Additional paid-in capital | | 392,234 | | 380,502 | ||
| Accumulated deficit | | (396,723) | | (380,971) | ||
| Total Stockholders’ Equity | | (3,873) | | 123 | ||
| Total Liabilities and Stockholders’ Equity | | $9,308 | | $17,742 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.